3 completed, 2 unknown, 1 active not recruiting, 1 recruiting. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Unknown 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Mild Dementia: new trials by email Literature Review of Mild Dementia trials Research Report on Mild Dementia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease KDS2010, Placebo - Mild Cognitive Impairment (MCI), Mild Dementia | Phase 2 | Recruiting | NeuroBiogen Co., Ltd | 114 | 2025-08-06 | 2026-06-22 |
| A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) SAGE-718, SAGE-718-matching Placebo - Mild Cognitive Impairment, Mild Dementia | Phase 2 | Completed | Supernus Pharmaceuticals, Inc. | 174 | 2022-11-29 | 2025-09-15 |
| A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD Biological/Vaccine: Bacillus Calmette-Guerin (BCG) - Mild Cognitive Impairment, Mild Dementia | Phase 2 | Completed | Steven E Arnold, MD | 15 | 2022-03-25 | 2025-04-13 |
| Cognitive Effects of Roflumilast in (a)MCI and Mild Dementia Patients Roflumilast, Placebo oral tablet - Mild Cognitive Impairment, Mild Dementia | Phase 2 | Unknown | Maastricht University Medical Center | 81 | 2021-11-19 | 2022-04-21 |
| A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) SAGE-718 - Alzheimer Disease, Cognitive Dysfunction | Phase 2 | Completed | Supernus Pharmaceuticals, Inc. | 26 | 2020-12-07 | 2025-09-15 |
| NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking) Placebo Oral Capsule, NYX-458 - Mild Cognitive Impairment, Mild Dementia | Phase 2 | Active not recruiting | Aptinyx | 99 | 2019-11-14 | 2022-10-27 |
| Clinical Trial of a Low Protein Diet in Patients With Cognitive Impairment Fasting-Mimicking Diet ProlonADTM - Mild Cognitive Impairment, Mild Dementia | Phase 1 / Phase 2 | Unknown | University of Genova | 40 | 2019-11-01 | 2022-07-29 |
Cognitive Dysfunction (7) · Alzheimer Disease (4) · Lewy Body Disease (1) · Parkinson Disease (1)
Cognition Disorders (7) · Mental Disorders (7) · Neurocognitive Disorders (7) · Brain Diseases (5) · Central Nervous System Diseases (5) · Dementia (5) · Nervous System Diseases (5) · Neurodegenerative Diseases (5) · Tauopathies (4) · Basal Ganglia Diseases (1) · Movement Disorders (1) · Parkinsonian Disorders (1) · Synucleinopathies (1)
BCG Vaccine (1) · Biological Products (1) · Phosphodiesterase 4 Inhibitors (1) · Roflumilast (1)
Supernus Pharmaceuticals, Inc. (2) · Aptinyx (1) · Maastricht University Medical Center (1) · NeuroBiogen Co., Ltd (1) · Steven E Arnold, MD (1) · University of Genova (1)
United States (4) · Italy (1) · Netherlands (1) · Puerto Rico (1) · South Korea (1)
Arjan Blokland, Prof. Dr. (1) · Frans Verhey, Prof. Dr. (1) · Inez Ramakers, Dr. (1) · Jos Prickaerts, Prof. Dr. (1) · Sangwook Kim, Chief Executive Officer (1) · Steven Arnold, MD (1)